Impact of a computerized antithrombotic risk assessment tool on the prescription of thromboprophylaxis in Atrial Fibrillation: Hospital Setting

Clinical and Applied Thrombosis/Hemostasis

Volumn 24, Issue 1, 2018, Pages 85-92

  Pandya, E ^a   Masood, N ^b   Wang, Y ^a   Krass, I ^c   Bajorek, B ^a,d  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b Building 52   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Anticoagulants; Antithrombotic therapy; Atrial fibrillation; Stroke; Thromboprophylaxis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMPUTERIZED ANTITHROMBOTIC RISK ASSESSMENT TOOL; DECISION MAKING; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL NORMALIZED RATIO; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THROMBOSIS PREVENTION; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; THROMBOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DIAGNOSIS, COMPUTER-ASSISTED; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; THROMBOSIS; WARFARIN;

EID: 85040781195     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616670031     Document Type: Article

References (31)

1. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation patterns of omission. Stroke. 2000;31(6):1217-1222.
2. Krass I, Ogle S, Duguid M, Shenfield G, Bajorek B. The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Austr J Ageing. 2002;21(1):36-41.
3. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J. 1999;137(2):307-312.
4. Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150(1):83-86.
5. Kutner M, Nixon G, Silverstone F. Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991; 151(10):1950-1953.
6. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155(3):277-281.
7. Launbjerg J, Egeblad H, Heaf J, Nielsen N, Fugleholm A, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. Arch Intern Med. 1991;229(4):351-355.
8. Landefeld CS, Goldman OL. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87(2):144-152.
9. Peterson G. Rational drug usage in the elderly: walking the fine line between polypharmacy and undertreatment. Austr Pharm. 2001;20(4):248-254.
10. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke. 2008;39(1):7-9.
11. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651-745.
12. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation American College of Chest Physicians evidencebased clinical practice guidelines. CHEST J. 2008;133(6 suppl): 546S-5492S.
13. Bajorek BV, Masood N, Krass I. Development of a computerised antithrombotic risk assessment tool (CARAT) to optimise therapy in older persons with atrial fibrillation. Austr J Ageing. 2012; 31(2):102-109.
14. Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005;53(11):1912-1920.
15. Wang Y, Bajorek B. Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf. 2014;5(1):21-37.
16. Evidence summary on oral anticoagulants and stroke prevention in atrial fibrillation. NPS Medicinewise [Internet]. http://www.nps.org.au/medicines/heart-blood-and-blood-vessels/anti-clotting-medicines/for-individuals/anticoagulant-medicines/forhealth-professionals/evidence-summary/atrial-fibrillation. Published May 8, 2014 Accessed September 18, 2016.
17. Novel oral anticoagulants for non-atrial fibrillation indications: utilisation analysis-drug utilisation sub-committee (DUSC) October 2014. https://www.google.co.uk/webhp?sourceid=chromeinstant&ion=1&espv=2&ie=UTF-8#q=DateþofþdabigatranþPBSþlistingþforþAF. Published October 2014. Updated March 6, 2015. Accessed September 12, 2016.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc. 2001;285(22):2864-2870.
19. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest J. 2010;137(2): 263-272.
20. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest J. 2010;138(5):1093-1100.
21. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3):713-719.
22. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
23. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk- prediction scores in patientswith atrial fibrillation undergoing anticoagulation: the amadeus (Evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J AmColl Cardiol. 2012;60(9):861-867.
24. Zimetbaum PJ, Thosani A, Yu H-T, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123(5):446-453.
25. Krass I, Ogle SJ, Duguid MJ, Shenfield GM, Bajorek BV. The impact of age on antithrombotic use in elderly patients with nonvalvular atrial fibrillation. Austr J Ageing. 2002;21(1):36-41.
26. Oliveira R, Grilo S, Moreira C, et al. A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation. Rev Port Cardiol. 2014;33(2):89-94.
27. Bo S, Valpreda S, Scaglione L, et al. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. BMC Public Health. 2007; 7(1):203.
28. Altmann DR, Kühne M, Sticherling C, Osswald S, Schaer BA. Use of the CHADS2 risk score to guide antithrombotic treatment in patients with atrial fibrillation—room for improvement. Swiss Med Wkly. 2010;140(5):73.
29. Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.
30. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing. 2011;40(6):675-683.
31. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013(1):464-470.